Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 8;25(1):106.
doi: 10.1186/s12905-025-03617-2.

Cardiometabolic markers and serum amh levels in PCOS: can AMH serve as a surrogate cardiometabolic markeR?

Mohammad Ashraf Ganie  1 , Neena Malhotra  2 , Puthiyaveetil Khadar Jabbar  3 , Sarita Aggarwal  4 , Roya Rozati  5 , Rakesh Sahay  6 , Subhankar Chowdhary  7 , Saloni Kamboj  8 , Imtiyaz Ahmad Wani  1 , Taruna Arora  9 , Prasanta Kumar Bhattacharya  10 , Khalid Ul Islam Rather  1
Affiliations

Cardiometabolic markers and serum amh levels in PCOS: can AMH serve as a surrogate cardiometabolic markeR?

Mohammad Ashraf Ganie et al. BMC Womens Health. .

Abstract

Objective: To study the cardiometabolic markers in women in with polycystic ovary syndrome (PCOS) across all phenotypes and its correlation with serum anti-mullerian hormone (AMH) levels.

Methodology: In cross-sectional community-based study aimed to determine the prevalence of PCOS among women aged 19-39 years over 5 years (2018-2022), 10,109 women were found to be eligible from 14,061 approached through a pre validated questionnaire. Out of this cohort, 201 women were diagnosed prior, and from the 2314 probable cases on detailed clinical, ultrasound and hormonal evaluation as per Rotterdam criteria, 860 were true cases. Healthy women from the same community matched for age and BMI, were taken as controls (1174). Both PCOS and healthy controls were assessed for cardio-metabolic indices, including anthropometry (BMI, Waist Circumference (WC), Waist to Hip Ratio (WHR), biochemistry (OGTT with 75 g glucose, lipid profile, Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), visceral adiposity index [VAI], lipid accumulation product [LAP]) and fasting and post prandial insulin. Other hormone assays and AMH levels were also assessed in PCOS and controls. Correlation between serum AMH and cardiometabolic indices was calculated for cases using Pearson's method. Data was analysed using STATA version 18.

Main outcome measure(s): Cardio-metabolic profile including obesity/overweight, hypertension, insulin resistance, dyslipidemia among PCOS women and their different phenotypes, comparison with controls and correlation with serum AMH levels in cases.

Result(s): In the baseline characteristics, PCOS group had higher systolic and diastolic blood pressure, fasting blood sugar, 2 h oral glucose tolerance test (OGTT), fasting, 30 min and two hours post OGTT insulin levels than control group. In lipid profile, PCOS group had lower High Density Lipoprotein-Cholestrol (HDL-C) and higher low Density Lipoprotein-Cholestrol (LDL-C) levels. HOMA-IR, VAI, LAP were significantly higher in PCOS group. When AMH was correlated with various cardio-metabolic indices in women with PCOS, significant positive correlation was found with BMI, waist circumference, triglycerides and very low Density Lipoprotein cholestrol (VLDL-C) VLDL levels. While correlating AMH with cardio-metabolic indices in different phenotypes, PCOS phenotype A, C, and D suggested a significant positive correlation with BMI, waist circumference, post -prandial blood sugar at 30 min and VLDL-C, while phenotype B correlated only with BMI and VLDL levels.

Conclusion(s): A positive correlation could be seen between serum AMH and anthropometric and lipid profile parameters in Indian PCOS women. No such correlation can be established between other insulin resistance markers.

Keywords: Cardiometabolic markers, serum AMH levels; Polycystic ovary syndrome.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval: Ethics approval was taken from all the respective sites with SKIMS being the coordinating centre(IEC, SKIMS, 107/2016). Consent for publication: All the subjects provided a written informed consent. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Cardiometabolic Indices of PCOS
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016;106(1):6–15. - PubMed
    1. Wekker V, van Dammen L, Koning A, Heida KY, Painter RC, Limpens J, et al. Long-term cardiometabolic disease risk in women with PCOS: a systematic review and meta-analysis. Hum Reprod Update. 2020;26(6):942–60. - PMC - PubMed
    1. Kazemi M, Pierson RA, Lujan ME, Chilibeck PD, McBreairty LE, Gordon JJ, et al. Comprehensive evaluation of type 2 diabetes and cardiovascular disease risk profiles in reproductive-age women with polycystic ovary syndrome: a large Canadian cohort. J Obstet Gynaecol Can. 2019;41(11):1453–60. - PubMed
    1. Lim SS, Kakoly NS, Tan JWJ, Fitzgerald G, Bahri Khomami M, Joham AE, et al. Metabolic syndrome in polycystic ovary syndrome: a systematic review, meta-analysis and meta-regression. Obes Rev. 2019;20(2):339–52. - PubMed
    1. Otaghi M, Azami M, Khorshidi A, Borji M, Tardeh Z. The association between metabolic syndrome and polycystic ovary syndrome: a systematic review and meta-analysis. Diabetes Metab Syndr. 2019;13(2):1481–9. - PubMed